Role of PACAP in migraine: An alternative to CGRP?

Song Guo, Inger Jansen-Olesen, Jes Olesen, Sarah Louise Christensen*

*Corresponding author af dette arbejde
18 Citationer (Scopus)

Abstract

Migraine is a widespread and debilitating neurological condition affecting more than a billion people worldwide. Thus, more effective migraine therapies are highly needed. In the last decade, two endogenous neuropeptides, calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP), were identified to be implicated in migraine. Recently, introduction of monoclonal antibodies (mAbs) blocking the CGRP is the most important advance in migraine therapy for decades. However, 40% of patients are unresponsive to these new drugs. We believe that PACAP may be involved in these patients. Like CGRP, PACAP is located to sensory nerve fibers, it dilates cranial arteries, it causes migraine when infused into patients and it is a peptide that lends itself to antibody therapy. Also, recent studies suggest that the PACAP pathway is independent of the CGRP pathway. Understanding the signaling pathways of PACAP may therefore lead to identification of novel therapeutic targets of particular interest in patients unresponsive to anti-CGRP therapy. Accordingly, neutralizing mAb to PACAP is currently in clinical phase II development. The aim of the present review is, therefore, to give a thorough account of the existing data on PACAP, its receptors and its relation to migraine.

OriginalsprogEngelsk
Artikelnummer105946
TidsskriftNeurobiology of Disease
Vol/bind176
ISSN0969-9961
DOI
StatusUdgivet - 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Role of PACAP in migraine: An alternative to CGRP?'. Sammen danner de et unikt fingeraftryk.

Citationsformater